Ahold Delhaize publishes 2022 Annual Report and issues convocation for 2023 Annual General Meeting of shareholders
Zaandam, The Netherlands, March 1, 2023 – Ahold Delhaize today publishes its 2022 Annual Report, an integrated report that provides an overview of the Company’s financial and ESG performance in 2022. Reflecting the fact that Ahold Delhaize is a family of great local brands serving millions of customers every day, the theme of this annual report is 'Local matters'. Our brands understand the unique needs of their local communities and customers, and by leveraging the scale and efficiency of a global company, they can offer them best-in-class digital solutions and make sustainable and healthy food accessible to everyone. The report will be on the agenda of the Annual General Meeting of Shareholders (AGM), which will be held on April 12, 2023.
Frans Muller, CEO of Ahold Delhaize, said: “2022 was a challenging year, that has put a strain on associates and on the communities – particularly as a result of the war in Ukraine. I’m grateful and proud of the people across our brands who have provided comfort, food and work to those affected and those fleeing the violence. We also saw the impact on people’s mental well-being – which was already under pressure after two difficult years of the COVID-19 pandemic. Our brands worked hard to support associates, continuing to invest in mental health and overall well-being.
In response to these circumstances, the brands remained laser focused on keeping grocery prices as low as possible and make healthy food options accessible to everyone by investing in high-quality own-brand products, expanding the range of price-entry products, and offer more personalized discounts through their loyalty programs. We have doubled down on our Save For Our Customers cost savings program that reached a record level of €979 million in 2022. In addition, our brands made significant donations to local communities, adding up to a total value of €218 million in cash and monetary value of food and products.
We have made substantial progress in our Leading Together strategy and within our growth drivers of e-commerce and digitalization, health and sustainability, cultivating talent, and operational excellence. One example is the significant increase in our interim scope 3 CO2 emissions reduction target to 37% by 2030, in line with the UN goal of keeping global warming below 1.5°C. This not only demonstrates our commitment to our considerable sustainability ambitions, but also our aspiration to play a leading role in driving sustainability across the food retail sector and our value chain.
By investing in our future and in the interests of all of our company's stakeholders, including employees and shareholders, we will continue to be able to take care of customers throughout the local communities our brands serve, even in these difficult times."
Looking forward to 2023, Ahold Delhaize expects challenging macro-economic conditions to continue. The company remains focused on its omnichannel customer experience to enable customers to shop whenever and wherever they want, and continue to provide affordable and healthy food options. In addition, the company will increase its Capex investments to 2.5 billion euros. This will include investments in digital and online capabilities as well as in initiatives that serve our healthy and sustainable targets.
Ahold Delhaize’s 2022 Annual Report will be on the agenda of the Annual General Meeting of Shareholders (AGM), which will be held on April 12, 2023. The convocation, the agenda (including explanatory notes), and other relevant documentation for the AGM are available here.
The 2022 Annual Report is available here.
-- ENDS --
This communication includes forward-looking statements. All statements other than statements of historical facts may be forward-looking statements. Words and expressions such as provides, offer, will, continu(e)/(ing), progress, strategy, in line, commitment, ambitions, aspiration, looking forward, expects, remains or other similar words or expressions are typically used to identify forward-looking statements.
Forward-looking statements are subject to risks, uncertainties and other factors that are difficult to predict and that may cause actual results of Koninklijke Ahold Delhaize N.V. (the “Company”) to differ materially from future results expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risk factors set forth in the Company’s public filings and other disclosures. Forward-looking statements reflect the current views of the Company’s management and assumptions based on information currently available to the Company’s management. Forward-looking statements speak only as of the date they are made and the Company does not assume any obligation to update such statements, except as required by law.
For more information
- Press office: +31 88 6595134 / email@example.com
- Investor relations: +31 88 659 5213 / firstname.lastname@example.org
- Social media: Instagram: @Ahold-Delhaize | LinkedIn: @Ahold-Delhaize | Twitter: @AholdDelhaize
About Ahold Delhaize
Ahold Delhaize is one of the world’s largest food retail groups and a leader in both supermarkets and e-commerce. Its family of great local brands serves 60 million customers each week, both in stores and online, in the United States, Europe and Indonesia. Together, these brands employ more than 414,000 associates in 7,659 grocery and specialty stores and include the top online retailer in the Benelux and the leading online grocers in the Benelux and the United States. Ahold Delhaize brands are at the forefront of sustainable retailing, sourcing responsibly, supporting local communities and helping customers make healthier choices. The company’s focus on four growth drivers – drive omnichannel growth, elevate healthy and sustainable, cultivate best talent and strengthen operational excellence – is helping to fulfil its purpose, achieve its vision and prepare its brands and businesses for tomorrow. Headquartered in Zaandam, the Netherlands, Ahold Delhaize is listed on the Euronext Amsterdam and Brussels stock exchanges (ticker: AD) and its American Depositary Receipts are traded on the over-the-counter market in the U.S. and quoted on the OTCQX International marketplace (ticker: ADRNY). For more information, please visit: www.aholddelhaize.com.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS23.3.2023 01:31:57 CET | Press release
SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). On the question, “Is the available evidence sufficient to conclude that a reduction in plasma neurofilament light chain (NfL) concentration in tofersen-treated patients is reasonably likely to predict clinical benefit of tofersen for treatment of patients with SOD1-ALS?” the Committee voted unanimously yes (9 yes to 0 no), for consideration of a potential accelerated approval. On the second question, “Does the clinical data from the placebo-controlled study and available long-term extension study results, with additional supporting res
GN Store Nord announces change to the Board of Directors22.3.2023 22:22:29 CET | Press release
Due to sudden serious health issues in the family, Montserrat Maresch Pascual has decided to step down from the Board of Directors of GN Store Nord A/S. The Chairmanship assesses that the remaining five members of the Board possess all the relevant competencies and experience to govern the company. Consequently, GN’s Board of Directors as of today consists of Jukka Pekka Pertola (Chair), Klaus Holse (Deputy chair), Anette Weber, Hélène Barnekow, Ronica Wang, and members elected by the employees: Leo Larsen, Cathrin Inge Hansen, and Claus Holmbeck-Madsen. For further information, please contact: Investor Relations Anne Sofie Staunsbæk Veyhe +45 45 75 85 06 Rune Sandager +45 45 75 92 57 Media Relations Steen Frentz Laursen +45 20 65 34 20 About GN GN facilitates communication between people through intelligent hearing, audio, video, and gaming technology. Inspired by people and driven by our passion for innovation, we leverage technologies to deliver unique user experiences that bring pe
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 202222.3.2023 22:05:00 CET | Press release
ERYTECH Provides Business and Financial Update for the Fourth Quarterand Full Year 2022 Combination with Pherecydesannounced, intending to create a global leader in extended phage therapies targeting antimicrobial resistant pathogenic bacteria Deep restructuring implemented; team size reduced by approximately 75% since start of 2022Cash and cash equivalents of €38.8million ($41.5 million) at the end of December 2022 Cambridge, MA (U.S.) and Lyon (France),March 22, 2023– ERYTECH Pharma (Nasdaq & Euronext: ERYP),aclinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial updatefor thefourth quarterand full year of2022. “After the disappointing results of our Phase 3 trial in pancreatic cancer, we have pursued during 2022 a consistent strategy to maximize the remaining value for our shareholders through strategic partnering. We sold our US manufacturing site, sharply
Hvidbjerg Banks ordinære generalforsamling den 22. marts 202322.3.2023 21:48:49 CET | pressemeddelelse
Formand Henrik H. Galsgaard udpegede advokat Rasmus Kronborg, Thisted til dirigent i henhold til vedtægternes § 9. Rasmus Kronborg takkede for valget og konstaterede, at generalforsamlingen var korrekt indvarslet og beslutningsdygtig med hensyn til generalforsamlingens dagsorden, som blev gennemgået. Dagsordenens punkt 1: Formand Henrik H. Galsgaard aflagde på bestyrelsens vegne mundtlig beretning om bankens virksomhed i det forløbne år. På grund af kommende kapitalkrav forventes der ikke udbetalt udbytte i de kommende år. Der var ikke kommet bemærkninger eller spørgsmål, hvorefter dirigenten konstaterede, at beretningen var taget til efterretning. Dagsordenens punkt 2 og 3: Bankdirektør Jens Odgaard fremlagde årsrapporten til godkendelse og årsrapporten blev godkendt. Årets resultat t.kr. 25.172 blev vedtaget overført således: Udbytte 0 Rente hybrid kernekapital 975 Henlagt til egenkapitalen 24.197 I alt anvendt 25.172 Dagsordenens punkt 4: Bestyrelsesformand Henrik H. Galsgaard freml
CNH Industrial: Periodic Report on $300 Million Buyback Program. Completion of Second $50 million tranche and launch of Third $50 million tranche22.3.2023 21:30:00 CET | Press release
London, March 22, 2023 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that it has completed the second tranche of its $50 million share buyback (the “Second Tranche”) in the framework of its $300 million common share buyback program with the transaction described in the table below. The transaction, completed on March 13, 2023, reported in aggregate, was based on automatic orders placed with the Company’s broker (who made its trading decisions as to the timing of the purchases independently of the Company based on instructions given before the commencement of the Company’s closed period under the applicable regulations). After the purchases announced today and considering those previously executed under the Second Tranche, the total invested amount is approximately €46,863,453.43 ($49,999,997.50) for a total amount of 3,065,368 common shares purchased. DateNumber of common shares purchasedAverage price per share excluding feesConsideration excluding fees Consideration (**) exclu